Figure 2.
Association of response to initial pemetrexed-based chemotherapy (PBC) and survival after the PBC rechallenge. No significant differences were observed in (A) the progression-free survival after the PBC rechallenge (PFS2) or (B) the overall survival (OS) after the PBC rechallenge between the partial response (PR) and stable disease (SD) subgroups after initial treatment with PBC.